

Synthesis of 6-Substituted-4-Hydroxy-2-Pyridinones via Intramolecular Ketene Trapping of Functionalized Enamine-Dioxinones

Supporting Information

Bhavesh H. Patel,[†] Andrew M. Mason[‡] and Anthony G. M. Barrett^{*,†}

[†] *Department of Chemistry, Imperial College, London SW7 2AZ, England.*

[‡] *GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Herts SG1 2NY, England*

agm.barrett@imperial.ac.uk

Contents

General Methods	4
Experimental	5
General Procedure for the Synthesis of Acyl Imidazolides 7b–g	5
1-(3-Methylbutanoyl)-imidazole (7b)	5
1-(2-Benzyloxyethanoyl)-imidazole (7c)	5
2-(<i>tert</i> -Butyl 2-oxoethyl(methyl)carbamoyl)-imidazole (7d)	5
3-(<i>tert</i> -Butyl (1-carbonyl)piperidine-1-carboxylate)-imidazole (7e)	6
1-(4-Methoxybenzoyl)-imidazole (7f)	6
1-(2-Furoyl)-imidazole (7g)	6
General Procedure for the Synthesis of Functionalized Keto-dioxinones 4a–4g	7
2,2-Dimethyl-6-(2-oxopropyl)-4 <i>H</i> -1,3-dioxin-4-one (4a)	7
2,2-Dimethyl-6-(4-methyl-2-oxopentyl)-4 <i>H</i> -1,3-dioxin-4-one (4b)	7
6-(3-(Benzyloxy)-2-oxopropyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4c)	7
<i>tert</i> -Butyl 3-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)-2-oxopropyl(methyl)carbamate (4d)	8
<i>tert</i> -Butyl 3-(2-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)acetyl)piperidine-1-carboxylate (4e)	8
6-(2-(4-Methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4f)	9
6-(2-(Furan-2-yl)-2-oxoethyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4g)	9
<i>tert</i> -Butyl 4-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)-3-oxobutanoate (4h)	9
General Procedure for the Synthesis of 6-Substituted-4-Hydroxy-2-Pyridinones 1a–h	10
4-Hydroxy-6-methylpyridin-2(1 <i>H</i>)-one (1a)	10
4-Hydroxy-6-iso-butylpyridin-2(1 <i>H</i>)-one (1b)	10
6-(Benzyloxymethyl)-4-hydroxypyridin-2(1 <i>H</i>)-one (1c)	10
<i>tert</i> -Butyl (4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)methyl(methyl)carbamate (1d)	11
<i>tert</i> -Butyl 3-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)piperidine-1-carboxylate (1e)	11
4-Hydroxy-6-(4-methoxyphenyl)pyridin-2(1 <i>H</i>)-one (1f)	11
6-(Furan-2-yl)-4-hydroxypyridin-2(1 <i>H</i>)-one (1g)	12
<i>tert</i> -Butyl 2-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)acetate (1h)	12
1-Benzyl-4-hydroxy-6-methylpyridin-2(1 <i>H</i>)-one (8)	12
<i>N</i> -Benzyl-5-(benzylamino)3-oxohex-4-enamide (9)	13
¹ H and ¹³ C spectra	14
1-(3-Methylbutanoyl)-imidazole (7b)	14
1-(2-Benzyloxyethanoyl)-imidazole (7c)	16
2-(<i>tert</i> -Butyl 2-oxoethyl(methyl)carbamoyl)-imidazole (7d)	18

3-(<i>tert</i> -Butyl (1-carbonyl)piperidine-1-carboxylate)-imidazole (7e).....	20
1-(4-Methoxybenzoyl)-imidazole (7f)	22
1-(2-Furoyl)-imidazole (7g)	24
2,2-Dimethyl-6-(2-oxopropyl)-4 <i>H</i> -1,3-dioxin-4-one (4a)	26
2,2-Dimethyl-6-(4-methyl-2-oxopentyl)-4 <i>H</i> -1,3-dioxin-4-one (4b)	28
6-(3-(Benzyloxy)-2-oxopropyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4c)	30
<i>tert</i> -Butyl 3-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)-2-oxopropyl(methyl)carbamate (4d)	32
<i>tert</i> -Butyl 3-(2-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)acetyl)piperidine-1-carboxylate (4e) ...	34
6-(2-(4-Methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4f)	36
6-(2-(Furan-2-yl)-2-oxoethyl)-2,2-dimethyl-4 <i>H</i> -1,3-dioxin-4-one (4g)	38
<i>tert</i> -Butyl 4-(2,2-Dimethyl-4-oxo-4 <i>H</i> -1,3-dioxin-6-yl)-3-oxobutanoate (4h)	40
4-Hydroxy-6-methylpyridin-2(1 <i>H</i>)-one (1a)	42
4-Hydroxy-6-isobutylpyridin-2(1 <i>H</i>)-one (1b)	44
6-(Benzyloxymethyl)-4-hydroxypyridin-2(1 <i>H</i>)-one (1c)	46
<i>tert</i> -Butyl (4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)methyl(methyl)carbamate (1d).....	48
<i>tert</i> -Butyl 3-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)piperidine-1-carboxylate (1e).....	50
4-Hydroxy-6-(4-methoxyphenyl)pyridin-2(1 <i>H</i>)-one (1f)	52
6-(Furan-2-yl)-4-hydroxypyridin-2(1 <i>H</i>)-one (1g)	54
<i>tert</i> -Butyl 2-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)acetate (1h).....	56
1-Benzyl-4-hydroxy-6-methylpyridin-2(1 <i>H</i>)-one (8).....	58
<i>N</i> -Benzyl-5-(benzylamino)3-oxohex-4-enamide (9).....	60
References	62

General Methods. All reactions were carried out in oven-dried glassware under N₂, using commercially supplied solvents and reagents unless otherwise stated. THF and PhMe were redistilled from Na-Ph₂CO and Na respectively. Hexanes refers petroleum spirit b.p. 40–60 °C. Column chromatography was carried out on silica gel, using flash techniques (eluants are given in parenthesis). Analytical thin layer chromatography was performed on pre-coated silica gel F₂₅₄ aluminium plates with visualization under UV light or by staining using acidic vanillin spray reagent. Melting points were obtained using a melting point apparatus and are uncorrected. Infrared spectra were recorded neat unless otherwise stated. Indicative features of each spectrum are given with adsorptions reported in wavenumbers (cm⁻¹). ¹H NMR spectra were recorded at 400 or 500 MHz with chemical shifts (δ) quoted in parts per million (ppm) and coupling constants (*J*) recorded in Hertz (Hz). ¹³C NMR spectra were recorded at 101 or 126 MHz with chemical shifts (δ) quoted in ppm.

Experimental

General Procedure for the Synthesis of Acyl Imidazolides 7b–g. Carboxylic acid **6b–g** (4.0 mmol) in THF (8 mL) was cooled to 0 °C and carbonyl diimidazole (90%; 0.79 g, 4.4 mmol) was added portionwise over 5 min. After 1.5–2 h, the mixture was diluted with Et₂O (60 mL), H₂O (20 mL) added carefully and the layers separated. The organic layer was washed with H₂O (2 x 20 mL) and brine (25 mL), dried (MgSO₄) and rotary evaporated to give the acyl imidazolides **7b–g**, which was used in the next step without further purification.

1-Acetylimidazole (7a): commercially available.¹

1-(3-Methylbutanoyl)-imidazole (7b): 90%; colorless oil; R_f 0.15 (hexanes : EtOAc 1 : 1); ¹H NMR (acetone-*d*₆, 400 MHz) δ 8.30 (s, 1H), 7.64 (br m, 1H), 7.03 (br m, 1H), 2.94 (d, *J* = 6.8 Hz, 2H), 2.26 (m, 1H), 1.03 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 171.3, 138.4, 132.3, 118.0, 45.0, 26.9, 23.5 (2C).²

1-(2-Benzyloxyethanoyl)-imidazole (7c): 84%; white solid; R_f 0.12 (hexanes : EtOAc 1 : 1); ¹H NMR (acetone-*d*₆, 400 MHz) δ 8.31 (s, 1H), 7.64 (br m, 1H), 7.43–7.41 (m, 2H), 7.39–7.29 (m, 3H), 7.05 (br m, 1H), 4.89 (s, 2H), 4.73 (s, 2H); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 169.2, 139.5, 138.3, 132.2, 130.2 (2C), 129.8 (2C), 129.7, 117.7, 75.0, 70.9; HRMS (ESI) calcd C₁₂H₁₂N₂O₂: [M + H]⁺ 217.0977; found [M + H]⁺ 217.0967.³

2-(*tert*-Butyl 2-oxoethyl(methyl)carbamoyl)-imidazole (7d): 90%; white solid; R_f 0.10 (hexanes : EtOAc 1 : 1); ¹H NMR (acetone-*d*₆, 400 MHz) δ 8.34 (s, 1H, rotamer 1 and 2), 7.67 (br m, 1H, rotamer 1 and 2), 7.07 (br m, 1H, rotamer 1 and 2), 4.79 (s, 1.5H, rotamer 1), 4.76 (s, 1.5H, rotamer 2), 3.01 (s, 1.5H, rotamer 1), 2.98 (s, 1.5H, rotamer 2), 1.47 (s, 4.5H, rotamer 1), 1.35 (s, 4.5H, rotamer 2); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 168.9 (rotamer 1), 168.7 (rotamer 2), 157.6 (rotamer

1), 156.8 (rotamer 2), 138.2, 132.5, 117.8, 81.4 (rotamer 1), 81.3 (rotamer 2), 53.8 (rotamer 1), 53.3 (rotamer 2), 36.9 (rotamer 1), 36.8 (rotamer 2), 29.4 (3C, rotamer 1), 29.2 (3C, rotamer 2).⁴

3-(*tert*-Butyl (1-carbonyl)piperidine-1-carboxylate)-imidazole (7e): 96%; colorless gum; R_f 0.06 (hexanes : EtOAc 1 : 1); ^1H NMR (acetone- d_6 , 400 MHz) δ 8.37 (s, 1H), 7.68 (br m, 1H), 7.06 (br m, 1H), 4.35–4.04 (br m, 1H), 4.03–3.72 (br m, 1H), 3.51–2.87 (br m, 3H), 2.19–2.05 (br m, 1H), 1.95–1.77 (br m, 2H), 1.63–1.54 (br m, 1H), 1.41 (br s, 9H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 172.7, 138.4, 132.5, 118.0, 80.7, 48.3, 47.6, 46.5, 45.2, 43.1, 29.4 (3C), 25.7, 25.1 (contains rotamers); HRMS (ESI) calcd $\text{C}_{14}\text{H}_{21}\text{N}_3\text{O}_3$: $[\text{M} + \text{H}]^+$ 280.1661; found $[\text{M} + \text{H}]^+$ 280.1652.⁵

1-(4-Methoxybenzoyl)-imidazole (7f): 76%; off-white solid; R_f 0.10 (hexanes : EtOAc 1 : 1); ^1H NMR (acetone- d_6 , 400 MHz) δ 8.12 (s, 1H), 7.87 (m, 2H), 7.61 (br m, 1H), 7.15 (m, 2H), 7.12 (br m, 1H), 3.94 (s, 3H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 167.2, 165.9, 139.9, 134.5, 134.3, 132.1, 125.9, 120.1, 116.2, 116.1, 57.1.⁶

1-(2-Furoyl)-imidazole (7g): 77%; off-white solid; R_f 0.07 (hexanes : EtOAc 1 : 1); ^1H NMR (acetone- d_6 , 400 MHz) δ 8.53 (s, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.86 (br m, 1H), 7.66 (d, J = 4.0 Hz, 1H), 7.12 (br m, 1H), 6.85 (dd, J = 3.6, 1.6 Hz, 1H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 155.8, 150.6, 147.4, 139.5, 132.2, 124.4, 119.4, 114.9; HRMS (ESI) calcd $\text{C}_8\text{H}_6\text{N}_2\text{O}_2$: $[\text{M} + \text{H}]^+$ 163.0508; found $[\text{M} + \text{H}]^+$ 163.0501.⁷

General Procedure for the Synthesis of Functionalized Keto-dioxinones 4a–4g. *n*-BuLi in hexanes (2.5 M; 1.40 mL, 3.50 mmol) was added dropwise with stirring to hexamethyldisilazane (0.74 mL, 3.50 mmol) in THF (7 mL) at $-78\text{ }^{\circ}\text{C}$. After 20 min, dioxinone 5 (0.36 g, 2.50 mmol) in THF (1 mL) was added dropwise. After 1 h, Et_2Zn in hexanes (1.0 M; 3.50 mL, 3.50 mmol) was added slowly, and after a further 20 min, the mixture was allowed to warm up to $-20\text{ }^{\circ}\text{C}$. Imidazole 7a–g (3.00 mmol) in THF (1.5 mL) was added and the reaction mixture immediately warmed to $-10\text{ }^{\circ}\text{C}$. After 2.5–3 h, the reaction was quenched with 1 M aqueous HCl (20 mL), and the aqueous layer acidified to pH 1–2 using 1 M aqueous HCl. The product was extracted twice with EtOAc (2 x 50 mL) and the combined organic extracts dried (MgSO_4), rotary evaporated and chromatographed (hexanes : Et_2O 3 : 1 to 2 : 1 to 1 : 2) to give keto-dioxinones 4a–g.

2,2-Dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (4a): pale yellow solid; R_f 0.20 (hexanes : Et_2O 1 : 1); mp $48\text{--}51\text{ }^{\circ}\text{C}$ (hexanes : Et_2O 2 : 1); IR 1726, 1636, 1374, 1275, 1206, 1013 cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz) δ 5.29 (s, 1H), 3.31 (s, 2H), 2.19 (s, 3H), 1.66 (s, 6H); ^{13}C NMR (CDCl_3 , 101 MHz) δ 200.8, 164.3, 160.5, 107.0, 96.5, 47.7, 30.0, 24.8 (2C); HRMS (CI) calcd $\text{C}_9\text{H}_{12}\text{O}_4$: $[\text{M} + \text{H}]^+$ 185.0814; found: $[\text{M} + \text{H}]^+$ 185.0812. Anal. Calcd for $\text{C}_9\text{H}_{12}\text{O}_4$: C, 58.69; H, 6.57; Found: C, 58.75; H, 6.62.⁸

2,2-Dimethyl-6-(4-methyl-2-oxopentyl)-4H-1,3-dioxin-4-one (4b): 73%; yellow oil; R_f 0.55 (hexanes : Et_2O 1 : 1); IR 2959, 1719, 1635, 1372, 1271, 1201, 1013, 810 cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ 5.39 (s, 1H), 3.54 (s, 2H), 2.48 (d, $J = 6.8\text{ Hz}$, 2H), 2.14 (m, 1H), 1.69 (s, 6H), 0.93 (d, $J = 6.8\text{ Hz}$, 6H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 204.8, 167.3, 161.6, 108.4, 98.1, 53.1, 48.7, 26.1 (2C), 25.9, 23.6 (2C); HRMS (ESI) calcd $\text{C}_{12}\text{H}_{18}\text{O}_4$: $[\text{M} + \text{H}]^+$ 227.1283; found $[\text{M} + \text{H}]^+$ 227.1276.⁹

6-(3-(Benzyloxy)-2-oxopropyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4c): 63%; yellow oil; R_f 0.30 (hexanes : Et_2O 1 : 1); IR 1725, 1636, 1376, 1272, 1203, 1098, 1016 cm^{-1} ; ^1H NMR (acetone- d_6 , 400

MHz) δ 7.42–7.29 (m, 5H), 5.39 (s, 1H), 4.62 (s, 2H), 4.25 (s, 2H), 3.62 (s, 2H), 1.66 (s, 6H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 203.7, 166.9, 161.5, 139.8, 130.2 (2C), 129.6 (2C), 129.6, 108.5, 98.4, 76.7, 74.8, 45.0, 26.1 (2C); HRMS (ESI) calcd $\text{C}_{16}\text{H}_{18}\text{O}_5$: $[\text{M} + \text{H}]^+$ 291.1232; found $[\text{M} + \text{H}]^+$ 291.1230.¹⁰

***tert*-Butyl 3-(2,2-Dimethyl-4-oxo-4*H*-1,3-dioxin-6-yl)-2-oxopropyl(methyl)carbamate (4d):** 58%; white solid; R_f 0.36 (hexanes : Et_2O 1 : 1); mp 58–60 °C (hexanes : Et_2O 1 : 1); IR 1726, 1694, 1637, 1453, 1373, 1270, 1245, 1201, 1156, 1014, 895 cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ 5.41 (s, 0.45H, rotamer 1), 5.39 (s, 0.55H, rotamer 2), 4.19 (br s, 2H, rotamer 1 and 2), 3.55 (2s, 2H, rotamer 1 and 2), 2.87 (s, 1.65H, rotamer 2), 2.84 (s, 1.35H, rotamer 1), 1.68 (2s, 6H, rotamer 1 and 2), 1.44 (s, 4.05H, rotamer 1), 1.39 (s, 4.95H, rotamer 2); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 201.8, 166.7, 108.5, 98.3, 98.2, 81.0, 80.9, 60.2, 59.6, 45.5, 45.4, 36.8, 36.7, 29.4 (3C, rotamer 1), 29.4 (3C, rotamer 2), 26.2 (2C) (contains rotamers); HRMS (ESI) calcd $\text{C}_{15}\text{H}_{23}\text{NO}_6$: $[\text{M} + \text{Na}]^+$ 336.1423; found $[\text{M} + \text{H}]^+$ 336.1423. Anal. Calcd for $\text{C}_{15}\text{H}_{23}\text{NO}_6$: C, 57.50; H, 7.40; N, 4.47; Found: C, 57.39; H, 7.30; N, 4.39.

***tert*-Butyl 3-(2-(2,2-Dimethyl-4-oxo-4*H*-1,3-dioxin-6-yl)acetyl)piperidine-1-carboxylate (4e):** 73%; pale yellow gum; R_f 0.34 (hexanes : Et_2O 1 : 1); IR 1727, 1689, 1637, 1420, 1370, 1268, 1148, 1014 cm^{-1} ; ^1H NMR (acetone- d_6 , 400 MHz) δ 5.38 (s, 1H), 4.01 (br dd, $J = 13.6, 4.0$ Hz, 1H), 3.79 (br d, $J = 12.8$ Hz, 1H), 3.67 (br s, 2H), 3.06 (br t, $J = 10.2$ Hz, 1H), 2.89–2.82 (br m, 1H), 2.72–2.65 (br m, 1H), 2.05–2.02 (br m, 1H), 1.75–1.69 (br m, 1H), 1.67 (s, 6H), 1.63–1.54 (br m, 1H), 1.48–1.40 (br m, 1H), 1.43 (br s, 9H); ^{13}C NMR (acetone- d_6 , 101 MHz) δ 206.4, 167.3, 161.5, 108.5, 98.3, 80.7, 50.1, 46.8, 46.7, 29.5 (3C), 28.2, 26.2 (2C), 26.1 (2C), 25.9; HRMS (ESI) calcd $\text{C}_{18}\text{H}_{27}\text{NO}_6$: $[\text{M} + \text{Na}]^+$ 376.1736; found $[\text{M} + \text{Na}]^+$ 376.1731.

6-(2-(4-Methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4f): 67%; pale yellow solid; R_f 0.26 (hexanes : Et₂O 1 : 1); mp 77–78 °C (hexanes : Et₂O 1 : 1); IR 1721, 1680, 1634, 1597, 1375, 1256, 1205, 1170, 1016, 836, 810 cm⁻¹; ¹H NMR (acetone-*d*₆, 400 MHz) δ 8.03–7.99 (m, 2H), 7.08–7.05 (m, 2H), 5.47 (s, 1H), 4.08 (s, 2H), 3.91 (s, 3H), 1.66 (s, 6H); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 193.6, 168.2, 166.0, 161.6, 132.5 (2C), 131.2, 115.8 (2C), 108.5, 98.4, 57.0, 44.6, 26.1 (2C); HRMS (ESI) calcd C₁₅H₁₆O₅: [M + H]⁺ 277.1076; found [M + H]⁺ 277.1074. Anal. Calcd for C₁₅H₁₆O₅: C, 65.21; H, 5.84; Found: C, 65.21; H, 5.91.

6-(2-(Furan-2-yl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4g): 65%; pale orange solid; R_f 0.28 (hexanes : Et₂O 1 : 1); mp 64–65 °C (hexanes : Et₂O 1 : 1); IR 1720, 1677, 1634, 1464, 1376, 1271, 1250, 1200, 1014, 903, 769 cm⁻¹; ¹H NMR (acetone-*d*₆, 400 MHz) δ 7.90 (d, *J* = 1.2 Hz, 1H), 7.46 (d, *J* = 4.0 Hz, 1H), 6.72 (dd, *J* = 3.6, 1.6 Hz, 1H), 5.49 (s, 1H), 3.95 (s, 2H), 1.65 (s, 6H); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 183.3, 167.0, 161.5, 153.7, 149.7, 120.5, 114.5, 108.6, 98.6, 44.5, 26.1 (2C); HRMS (ESI) calcd C₁₂H₁₂O₅: [M + H]⁺ 237.0763; found [M + H]⁺ 237.0755. Anal. Calcd for C₁₂H₁₂O₅: C, 61.01; H, 5.12; Found: C, 61.10; H, 5.22.⁹

***tert*-Butyl 4-(2,2-Dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-oxobutanoate (4h):** off-white solid; R_f 0.20 (hexanes : Et₂O 1 : 1); mp 43–45 °C (hexanes : Et₂O 1 : 1); IR 1732, 1717, 1635, 1373, 1336, 1267, 1204, 1165, 1130, 1054, 1013, 850 cm⁻¹; ¹H NMR (acetone-*d*₆, 400 MHz) δ 5.40 (s, 1H), 3.68 (s, 2H), 3.55 (s, 2H), 1.68 (s, 6H), 1.46 (s, 9H); ¹³C NMR (acetone-*d*₆, 101 MHz) δ 198.8, 167.7, 166.5, 161.5, 108.5, 98.5, 83.1, 51.9, 48.4, 29.1 (3C), 26.1 (2C); HRMS (ESI) calcd C₁₄H₂₀O₆: [M – ^{*t*}Bu + H]⁺ 229.0712; found [M – ^{*t*}Bu + H]⁺ 229.0705. Anal. Calcd for C₁₄H₂₀O₆: C, 59.14; H, 7.09; Found: C, 59.11; H, 7.14.^{11,12}

General Procedure for the Synthesis of 6-Substituted-4-Hydroxy-2-Pyridinones 1a–h. Keto-dioxinone **4a–h** (0.60 mmol) and NH₄OAc (0.23 g, 3.00 mmol) were stirred in absolute EtOH (2.5 mL). After 2–3 h, the solvent was evaporated and EtOAc (10 mL) added. The resultant solid was filtered and the solvent evaporated to provide crude enamine-dioxinone **3a–h**, which in PhMe (5 mL), was added using a syringe pump to PhMe (50 mL) at reflux, over 30 min. After 4 h, the solvent was evaporated and the residue triturated with Et₂O (25 mL) to provide the desired pyridinone product **1a–h**.

4-Hydroxy-6-methylpyridin-2(1H)-one (1a): 91%: yellow/orange solid; mp 260 °C (dec.) (MeOH : acetone 1 : 1); IR 1596, 1531, 1443, 1349, 1255, 1230, 1170, 828 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.90 (s, 1H), 10.30 (s, 1H), 5.58 (d, *J* = 1.2 Hz, 1H), 5.32 (d, *J* = 2.4 Hz, 1H), 2.06 (s, 3H); ¹³C NMR (DMSO-*d*₆, 126 MHz) δ 167.4, 164.5, 145.8, 97.9, 95.6, 18.3; HRMS (ESI) calcd C₆H₇NO₂: [M + H]⁺ 126.0555; found [M + H]⁺ 126.0535.¹³

4-Hydroxy-6-iso-butylpyridin-2(1H)-one (1b): 92%: yellow/orange solid; mp 252 °C (dec.) (MeOH : acetone 1 : 1); IR 1593, 1535, 1431, 1392, 1359, 1258, 1229, 1166, 837 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.90 (s, 1H), 10.39 (s, 1H), 5.57 (d, *J* = 2.4 Hz, 1H), 5.35 (d, *J* = 2.0 Hz, 1H), 2.21 (d, *J* = 7.2 Hz, 2H), 1.88 (m, 1H), 0.84 (d, *J* = 6.8 Hz, 6H); ¹³C NMR (DMSO-*d*₆, 101 MHz) δ 167.4, 164.7, 148.9, 98.2, 96.0, 41.0, 27.5, 21.8 (2C); HRMS (ESI) calcd C₉H₁₃NO₂: [M + H]⁺ 168.1025; found [M + H]⁺ 168.1021.

6-(Benzyloxymethyl)-4-hydroxypyridin-2(1H)-one (1c): 89%: pale brown solid; mp 155–157 °C (MeOH : acetone 1 : 1); IR 1631, 1603, 1449, 1359, 1246, 1161, 1101, 832 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 11.03 (s, 1H), 10.54 (s, 1H), 7.39–7.30 (m, 5H), 5.87 (d, *J* = 2.4 Hz, 1H), 5.44 (d, *J* = 2.0 Hz, 1H), 4.53 (s, 2H), 4.27 (s, 2H); ¹³C NMR (DMSO-*d*₆, 101 MHz) δ 167.2, 164.4, 146.1, 137.8, 128.2 (2C), 127.5 (3C), 97.4, 97.2, 71.8, 67.4; HRMS (ESI) calcd C₁₃H₁₃NO₃: [M + H]⁺

232.0974; found $[M + H]^+$ 232.0963. Anal. Calcd for $C_{13}H_{13}NO_3$: C, 67.52; H, 5.67; N, 6.06; Found: C, 67.36; H, 5.56; N, 5.95.

***tert*-Butyl (4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)methyl(methyl)carbamate (1d):** 93%: off-white solid; mp 159–161 °C (MeOH : acetone 1 : 1); IR 1603, 1442, 1389, 1365, 1236, 1144, 832 cm^{-1} ; 1H NMR (DMSO- d_6 , 500 MHz) δ 10.22 (br s, 2H), 5.62 (d, J = 2.0 Hz, 1H), 5.44 (d, J = 2.0 Hz, 1H), 4.14 (s, 2H), 2.85 (s, 3H), 1.42 (s, 9H); ^{13}C NMR (DMSO- d_6 , 126 MHz) δ 166.9, 163.8, 154.5, 146.1, 96.2, 96.0, 78.8, 48.7, 34.1, 27.5 (3C); HRMS (ESI) calcd $C_{12}H_{18}N_2O_4$: $[M + H]^+$ 255.1345; found $[M + H]^+$ 255.1337. Anal. Calcd for $C_{12}H_{18}N_2O_4$: C, 56.68; H, 7.13; N, 11.02; Found: C, 56.59; H, 7.07; N, 10.94.

***tert*-Butyl 3-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)piperidine-1-carboxylate (1e):** 92%: off-white solid; mp 190–192 °C (MeOH : acetone 1 : 1); IR 1701, 1658, 1623, 1583, 1418, 1364, 1164, 1136, 834 cm^{-1} ; 1H NMR (DMSO- d_6 , 500 MHz) δ 10.20 (br s, 2H), 5.66 (d, J = 2.0 Hz, 1H), 5.43 (d, J = 2.0 Hz, 1H), 3.97–3.90 (m, 1H), 3.89–3.83 (m, 1H), 2.97–2.93 (br m, 2H), 2.86–2.80 (br m, 1H), 2.55–2.50 (br m, 1H), 1.93–1.90 (br m, 1H), 1.70–1.66 (br m, 1H), 1.64–1.60 (br m, 1H), 1.43 (br s, 9H); ^{13}C NMR (DMSO- d_6 , 126 MHz) δ 166.8, 164.0, 153.4, 150.7, 96.1, 95.9, 78.2, 46.9, 43.0, 38.7, 28.6, 27.5 (3C), 23.6; HRMS (ESI) calcd $C_{15}H_{22}N_2O_4$: $[M + H]^+$ 295.1658; found $[M + H]^+$ 295.1655. Anal. Calcd for $C_{15}H_{22}N_2O_4$: C, 61.21; H, 7.53; N, 9.52; Found: C, 61.13; H, 7.62; N, 9.58.

4-Hydroxy-6-(4-methoxyphenyl)pyridin-2(1H)-one (1f): 90%: pale yellow solid; mp 275 °C (dec.) (MeOH : acetone 1 : 1); IR 1607, 1574, 1510, 1369, 1327, 1246, 1210, 1177, 1028, 820 cm^{-1} ; 1H NMR (DMSO- d_6 , 400 MHz) δ 11.14 (br s, 1H), 10.55 (br s, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 6.05 (d, J = 2.0 Hz, 1H), 5.51 (d, J = 2.0 Hz, 1H), 3.80 (s, 3H); ^{13}C NMR (DMSO- d_6 , 101 MHz) δ 167.3, 164.8, 160.4, 146.9, 128.0 (2C), 125.7, 114.1 (2C), 96.9, 96.5, 55.2; HRMS (ESI)

calcd C₁₂H₁₁NO₃: [M + H]⁺ 218.0817; found [M + H]⁺ 218.0813. Anal. Calcd for C₁₂H₁₁NO₃: C, 66.35; H, 5.10; N, 6.45; Found: C, 66.24; H, 5.03; N, 6.48.¹⁴

6-(Furan-2-yl)-4-hydroxypyridin-2(1H)-one (1g): 90%: pale brown solid; mp 240 °C (dec.) (MeOH : acetone 1 : 1); IR 1597, 1571, 1485, 1446, 1370, 1288, 1217, 1019, 834, 737 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 11.24 (br s, 1H), 10.70 (br s, 1H), 7.83 (br m, 1H), 7.33 (br d, *J* = 3.2 Hz, 1H), 6.64 (br d, *J* = 1.6 Hz, 1H), 6.20 (br d, *J* = 1.6 Hz, 1H), 5.50 (br d, *J* = 2.0 Hz, 1H); ¹³C NMR (DMSO-*d*₆, 101 MHz) δ 167.1, 164.4, 146.7, 144.7, 137.6, 112.2, 110.1, 97.3, 94.8; HRMS (ESI) calcd C₉H₇NO₃: [M + H]⁺ 178.0504; found [M + H]⁺ 178.0501. Anal. Calcd for C₉H₇NO₃: C, 61.02; H, 3.98; N, 7.91; Found: C, 61.12; H, 4.02; N, 7.85.

tert-Butyl 2-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)acetate (1h): 84%: off-white solid; mp 278 °C (dec.) (MeOH : acetone 1 : 1); IR 1730, 1634, 1602, 1441, 1365, 1332, 1267, 1218, 1148, 850 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.98 (br s, 1H), 10.46 (br s, 1H), 5.71 (d, *J* = 2.4 Hz, 1H), 5.40 (d, *J* = 2.4 Hz, 1H), 3.41 (s, 2H), 1.41 (s, 9H); ¹³C NMR (DMSO-*d*₆, 101 MHz) δ 168.0, 167.2, 164.4, 142.5, 99.6, 96.8, 80.7, 38.5, 27.6 (3C); HRMS (ESI) calcd C₁₁H₁₅NO₄: [M + H]⁺ 226.1079; found [M + H]⁺ 226.1069.


1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one (8). Keto-dioxinone **4a** (129 mg, 0.70 mmol), benzylamine (0.076 mL, 0.70 mmol) and molecular sieves 4Å (70 mg) were stirred in CH₂Cl₂ (2.5 mL). After 3 h, the solid was filtered and the solvent evaporated to provide the crude enamine-dioxinone (verified by ¹H NMR spectroscopy), which in PhMe (5 mL) and EtOAc (5 mL), was added using a syringe pump to PhMe (45 mL) at reflux, over 30 min. After 4 h, the solvent was evaporated and the residue triturated with Et₂O (25 mL) to provide the desired pyridinone product **8** (112 mg, 75%) as a pale yellow solid: mp 205–208 °C (MeOH : acetone 1 : 1); IR 1614, 1524, 1510, 1494, 1452, 1426, 1316, 1291, 1231, 1210, 1156, 832 cm⁻¹; ¹H NMR (DMSO-*d*₆, 400 MHz) δ 10.53


(br s, 1H), 7.32 (m, 2H), 7.23 (m, 1H), 7.08 (m, 2H), 5.80 (d, $J = 2.0$ Hz, 1H), 5.60 (d, $J = 2.4$ Hz, 1H), 5.19 (s, 2H), 2.16 (s, 3H); ^{13}C NMR (DMSO- d_6 , 101 MHz) δ 165.8, 164.0, 147.5, 137.7, 128.5 (2C), 126.8, 126.0 (2C), 100.4, 95.8, 45.2, 19.8; HRMS (ESI) calcd $\text{C}_{13}\text{H}_{13}\text{NO}_2$: $[\text{M} + \text{H}]^+$ 216.1025; found $[\text{M} + \text{H}]^+$ 216.1030.¹⁵

***N*-Benzyl-5-(benzylamino)3-oxohex-4-enamide (9)**: pale yellow solid; mp 106–108 °C (MeOH : acetone 1 : 1); IR 3306, 1639, 1604, 1567, 1536, 1515, 1495, 1450, 1314, 1249, 1067, 1028, 950, 805 cm^{-1} ; ^1H NMR (DMSO- d_6 , 400 MHz) δ 10.93 (br t, $J = 6.0$ Hz, 1H), 8.44 (br t, $J = 5.6$ Hz, 1H), 7.41–7.23 (m, 5H), 5.07 (s, 1H), 4.53 (d, $J = 6.0$ Hz, 2H), 4.28 (d, $J = 6.0$ Hz, 2H), 3.11 (s, 2H), 1.96 (s, 3H); ^{13}C NMR (DMSO- d_6 , 101 MHz) δ 189.4, 167.4, 163.9, 139.4, 138.3, 128.6 (2C), 128.1 (2C), 127.2, 127.1 (2C), 127.0 (2C), 126.6, 94.6, 49.4, 45.9, 42.0, 18.6; HRMS (ESI) calcd $\text{C}_{20}\text{H}_{22}\text{N}_2\text{O}_2$: $[\text{M} + \text{H}]^+$ 323.1760; found $[\text{M} + \text{H}]^+$ 323.1763.


¹H and ¹³C spectra


1-(3-Methylbutanoyl)-imidazole (7b)







1-(2-Benzyloxyethanoyl)-imidazole (7c)







2-(*tert*-Butyl 2-oxoethyl(methyl)carbamoyl)-imidazole (7d)







3-(*tert*-Butyl (1-carbonyl)piperidine-1-carboxylate)-imidazole (7e)







1-(4-Methoxybenzoyl)-imidazole (7f)







1-(2-Furoyl)-imidazole (7g)







2,2-Dimethyl-6-(2-oxopropyl)-4H-1,3-dioxin-4-one (4a)







2,2-Dimethyl-6-(4-methyl-2-oxopentyl)-4H-1,3-dioxin-4-one (4b)







6-(3-(Benzyloxy)-2-oxopropyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4c)







***tert*-Butyl 3-(2,2-Dimethyl-4-oxo-4*H*-1,3-dioxin-6-yl)-2-oxopropyl(methyl)carbamate (4d)**







***tert*-Butyl 3-(2-(2,2-Dimethyl-4-oxo-4*H*-1,3-dioxin-6-yl)acetyl)piperidine-1-carboxylate (4e)**







6-(2-(4-Methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4f)







6-(2-(Furan-2-yl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (4g)







***tert*-Butyl 4-(2,2-Dimethyl-4-oxo-4*H*-1,3-dioxin-6-yl)-3-oxobutanoate (4h)**







4-Hydroxy-6-methylpyridin-2(1H)-one (1a)







4-Hydroxy-6-isobutylpyridin-2(1H)-one (1b)







6-(Benzyloxymethyl)-4-hydroxypyridin-2(1H)-one (1c)







***tert*-Butyl (4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)methyl(methyl)carbamate (1d)**







***tert*-Butyl 3-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)piperidine-1-carboxylate (1e)**







4-Hydroxy-6-(4-methoxyphenyl)pyridin-2(1H)-one (1f)







6-(Furan-2-yl)-4-hydroxypyridin-2(1H)-one (1g)







***tert*-Butyl 2-(4-Hydroxy-6-oxo-1,6-dihydropyridin-2-yl)acetate (1h)**







1-Benzyl-4-hydroxy-6-methylpyridin-2(1H)-one (8)





***N*-Benzyl-5-(benzylamino)3-oxohex-4-enamide (9)**





References

- (1) Purchased from Sigma Aldrich Chemical Company, Inc.
- (2) Knoelker, H.-J.; Boese, R.; Doering, D.; El-Ahl, A.-A.; Hitzemann, R.; Jones, P. G. *Chem. Ber.* **1992**, *125*, 1939.
- (3) Bryan, V. J.; Chan, T.-H. *Tetrahedron Lett.* **1997**, *38*, 6493.
- (4) Nestorak, I. Y.; Tverdokhlebov, A. V.; Tolmachev, A. A.; Volovenko, Y. M. *Heterocycles* **2010**, *81*, 611.
- (5) Tanitame, A.; Oyamada, Y.; Ofuji, K.; Fujimoto, M.; Suzuki, K.; Ueda, T.; Terauchi, H.; Kawasaki, M.; Nagai, K.; Wachi, M.; Yamagishi, J.-I. *Bioorg. Med. Chem.* **2004**, *12*, 5515.
- (6) Zaramella, S.; Stroemberg, R.; Yeheskiely, E. *Eur. J. Org. Chem.* **2002**, *15*, 2633.
- (7) Kitagawa, T.; Kuroda, H.; Sasaki, H.; Kawasaki, K. *Chem. Pharm. Bull.* **1987**, *35*, 4294.
- (8) Patel, B. H.; Mason, A. M.; Patel, H.; Coombes, R. C.; Ali, S.; Barrett, A. G. M. *J. Org. Chem.* **2011**, .
- (9) Bach, T.; Kirsch, S. *Synlett* **2001**, *12*, 1974.
- (10) Sato, M.; Sakaki, J.-I.; Sugita, Y.; Yasuda, S.; Sakoda, H.; Kaneko, C. *Tetrahedron*, **1991**, *47*, 5689.
- (11) For procedure see: Navarro, I.; Basset, J.-F.; Hebbe, S.; Major, S. M.; Werner, T.; Howsham, C.; Brackow, J.; Barrett, A. G. M. *J. Am. Chem. Soc.* **2008**, *130*, 10293.
- (12) Kiegiel, J.; Jozwik, J.; Wozniak, K.; Jurczak, J. *Tetrahedron Lett.* **2000**, *41*, 4959.
- (13) Collie, J. N. *J. Chem. Soc.* **1891**, *59*, 607.
- (14) Ito, K.; Miyajima, S. *J. Heterocyclic Chem.* **1992**, *29*, 1037.
- (15) Castillo, S.; Ouadahi, H.; Herault, V. *Bull. Soc. Chim. Fr.* **1982**, 257.